DERMATA THERAPEUTICS DRMAW 深 沪
已收盘 05-08 16:00:00 美东时间
0.0144
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0144
- 总市值 0
- 52周最高 0.029
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.0103
- 委 比 -23.57%
- 总股本 --
- 历史最高 1.70
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dermata Therapeutics Secures Australian Patent Acceptance For Bioneedle System In Dermal Fillers
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering
04-02 20:38
Dermata Therapeutics Announces Private Placement Up To $12.4M
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and
2025-12-24 21:01
BRIEF-Dermata Therapeutics Announces Strategic Pivot To OTC Skin Care - SEC Filing
Nov 14 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA THERAPEUTICS INC - ANNOUNCES STRATEGIC PIVOT TO OTC SKIN CARE - SEC FILING DERMATA THERAPEUTICS INC - TO LAUNCH FIRST OTC ACNE KIT MID-2026 ...
2025-11-15 05:20
Dermata Therapeutics Announces Australian Patent Office Accept Patent Application For Spongilla Technology Combination As Method For Treating Acne
- This acceptance follow's Dermata's U.S. issued patent covering its Spongilla technology combination as a method to topically treat acne -- Dermata expects to launch a new once-weekly, Over-the-Counter (OTC)
2025-10-02 20:02
Dermata Therapeutics Announces Strategic Pivot To Prioritize Development And Distribution Of OTC Pharmaceutical Dermatology Focused Products
Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced a bold strategic pivot to prioritize the development and
2025-09-10 20:09
BRIEF-Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care
Sept 10 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA THERAPEUTICS INC: HAS WITHDRAWN ITS INVESTIGATIONAL NEW DRUG APPLICATION FOR XYNGARI WITH U.S. FOOD AND DRUG ADMINISTRATION DERMATA THERAPE...
2025-09-10 20:09
BRIEF-Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC Filing
May 21 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA THERAPEUTICS INC - POTENTIAL NDA FILING FOR XYNGARI IN H1 2028 - SEC FILING Source text: [ID:n0001641172-25-011873] Further company coverage...
2025-05-21 21:29
BRIEF-Dermata Therapeutics Inc - Announces Topline Results From Phase 3 Trial Of Xyngari - SEC Filing
April 15 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA THERAPEUTICS INC - ANNOUNCES TOPLINE RESULTS FROM PHASE 3 TRIAL OF XYNGARI - SEC FILING Source text: [ID:n0001654954-25-004265] Further co...
2025-04-15 21:15
BREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
- XYNGARI™ achieved its primary endpoints, demonstrating highly statistically significant and clinically meaningful improvement in acne - - XYNGARI™ is the first once-weekly topical product ...
2025-03-27 20:00
BRIEF-Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne
March 4 (Reuters) - Dermata Therapeutics Inc DRMA.O: DERMATA ANNOUNCES THAT LAST PATIENT COMPLETES LAST VISIT IN PIVOTAL XYNGARI™ PHASE 3 STAR-1 CLINICAL TRIAL FOR ACNE DERMATA THERAPEUTICS INC - TOPL...
2025-03-04 22:16
